Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Samir Kapadia, MD, Cleveland Clinic TAVR transcatheter aortic valve replacement

Q&A: Discussing TAVR trends with cardiologist Samir Kapadia of Cleveland Clinic

What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

hospital ward

Why cardiologists should pay close attention to rehospitalizations after TAVR or SAVR

A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.

An example of virtual pulmonary valve implant planning software showing a virtual transcatheter pulmonary valve with measurements implnated in the virtual anatomy of a congenital heart patient. This was part of a training class at the Society of Cardiovascular Computed Tomography (SCCT) 2022 meeting.

FDA makes clearance easier for cardiac device implant simulation software

The FDA is reclassifying interventional cardiovascular implant simulation software into the class II (special controls) regulatory category, which will make it easier for the technology to pass regulatory approval. 

The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

VIDEO: The importance of assessing TAVR valve durability

Brian Lindman, MD, discusses the tracking of TAVR devices for signs of deterioration and how to assess long-term durability.

Thumbnail

No antithrombotic therapy after TAVR? New research highlights potential benefits

The study, published in JACC: Cardiovascular Interventions, focused on data from more than 3,500 TAVR patients. 

Minima Stent Cedars Sinai adjustable children cardiology

Cardiologists explore the real-world potential of new adjustable stents for children

The new-look adjustable stents, not yet fully approved by the FDA, can be expanded as a child ages. The hope is that these stents will never need to be replaced.

Gabler Survivor Heart Valve Specialist TAVR

Mike Gabler, a heart valve specialist with Edwards Lifesciences, wins Survivor—and donates his $1M prize

Gabler, a Texas native, has two decades of experience in the cardiology space, spending the last 11 years with Edwards Lifesciences. He has also previously worked for both Medtronic and Boston Scientific.

An updated look at the latest self-expandable and balloon-expandable TAVR devices

Researchers have completed a new analysis of the Evolut Pro and Pro+ devices from Medtronic and the Sapien 3 Ultra devices from Edwards Lifesciences, sharing the results in JACC: Cardiovascular Interventions.

Displaying 329 - 336 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.